Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03724981 · ClinicalTrials.gov registry record · Phase 4
A Study Comparing the Dulaglutide Pen and the Semaglutide Pen
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 312
- Enrollment target
NCT03724981 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 312 participants.
The verdict
NCT03724981, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 312 participants
- Enrollment target
Study Summary
In this study participants will try out two different types of drug injection pens (dulaglutide and semaglutide) on a practice pad and decide which device they prefer. No study drug will be administered.
Interventions
- DRUG Dulaglutide Pen
- DRUG Semaglutide Pen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 2018-10-18 |
| Est. Completion | 2019-04-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03724981
The ClinicalTrials.gov registry entry for NCT03724981 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dulaglutide Pen is the first listed.
NCT03724981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03724981 about?
NCT03724981 is a clinical study titled "A Study Comparing the Dulaglutide Pen and the Semaglutide Pen". In this study participants will try out two different types of drug injection pens (dulaglutide and semaglutide) on a practice pad and decide which device they prefer. No study drug will be administered.
What is the current status of trial NCT03724981?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 312 participants. The study started on 2018-10-18. Estimated completion is 2019-04-12.
What interventions are being tested in trial NCT03724981?
The interventions under investigation include: Dulaglutide Pen (DRUG), Semaglutide Pen (DRUG).
Who is sponsoring clinical trial NCT03724981?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.